• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Waters and Genovis Enter Biopharmaceutical Partnership

    Frontage Acquires Ocean Ridge Biosciences

    AGC Biologics Expands Partnership with Rocket Pharmaceuticals

    TraceLink Introduces Opus Platform

    Evotec to Build Second Biologics Mfg. Facility in Toulouse
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lessons Learned: Choosing and Managing a CDMO

    Waters and Genovis Enter Biopharmaceutical Partnership

    AGC Biologics Expands Partnership with Rocket Pharmaceuticals

    TraceLink Introduces Opus Platform

    Evotec to Build Second Biologics Mfg. Facility in Toulouse
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    Adare Pharma Solutions

    Alcami

    Syngene

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Alcami

    PCI Pharma Services

    Almac Group

    Quotient Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Clinical Materials for Asthma and COPD Studies

    How to overcome inhaler blinding issues

    Related CONTENT
    • Epizyme Earns $10M GSK Milestone
    • GSK Invests $139M to Expand Benlysta Capacity
    • Quality Risk Management
    • Veeva Systems Expands Leadership Team
    • Mayne Pharma Acquires GSK Dermatology Assets
    Martin Lamb, Almac09.06.12
    Almost three quarters of the $35 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation or nasal spray technologies. The top five drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) attracted revenues of around $18.1 billion in 20111. Given the anticipated growth in this market, it is clear that there is a continued and growing need to support the development of double-blind clinical trials within these therapeutic areas that use inhalers as the mechanism for drug delivery.

    To support registration and marketing claims, new entrants to the asthma and COPD markets must run comparative trials against market leading products. When aiming to eliminate bias and ensure that the results of these trials are statistically valid, it would be preferable to perform these trials in a double-blind manner. However, how can blinding for products be achieved where physical differences are so extreme? Modification of the inhalation device or using the same device for both treatments is not feasible because the inhaler plays such a critical role in the dispersal and subsequent action of the active ingredient in the airways. This article will look at ways in which blinding of inhalers for double-blind trials can be achieved.

    Clinical Study Design
    Due to the unique designs of inhalation devices, companies often use a double-blind, double-dummy design to enable them to use their product in its planned market form. This approach also means that they do not need to ‘blind’ their own product as they could produce placebo using the same/similar formulation minus the active ingredient.

    While the developer of the innovator product can easily provide an active and placebo of its own inhaler, it is not possible to do this for the comparator. Active comparators may be purchased from the open market; however standard techniques for blinding cannot be used. Placebo units must be produced by converting active inhaler units by removing and replacing their active ingredients and inert materials.

    For legal and ethical reasons, it is important that the comparator units used in a clinical trial are distinct from the commercial product. A trial inhaler could contain active product or could be a placebo, so should appear different from the commercial product. This adds work to the production of clinical trial supplies because both the active and placebo product have to be changed in some way.

    Blinding Metered Dose Inhalers (MDIs)
    These inhalers consist of a plastic body (the actuator) into which an aerosol canister is inserted. Aerosol canisters contain active ingredient and propellants such as Hydrofluoroalkane (HFA). The base of the aerosol may be embossed with a trade name or batch number. Additional markings specific to the product (embossed markings, labels, inkjet printing) may also be present on the actuator body.

    Two basic approaches may be used to blinding MDI units. A double-blind design can be used if both the innovator product and the comparator are MDIs with similar size, shape and dimensions. Both products can be encased by a masking device. This is usually a large plastic actuator that covers the entire MDI, while still allowing it to function normally. This approach may be challenging as it’s rare to find two MDIs close enough in size and dimensions. This approach has been used successfully before, but it could be argued that it was too easy for the patient to remove the masking device and potentially unblind the study.

    A double-blind, double-dummy design is most commonly used. Contract manufacturers and generics companies involved in MDI manufacture are willing to sell aerosol canisters containing a propellant only. It may be possible to match exactly the size and appearance of the commercial MDI aerosol by identifying the parts used in its manufacture and sourcing identical parts off-the-shelf. Occasionally, the design of specific parts may be covered by a patent or may be produced on a ‘customer-specific’ basis by the manufacturer. If this is the case, parts that are close in appearance but not identical can be used. While the blind may not be perfect, the likelihood of a patient or investigator actually having two different units side-by-side and making a direct comparison should be taken into account.

    If such a scenario is unlikely, a slight difference may not be an issue.

    If sourcing placebo aerosols from a third party, careful planning is necessary to minimize costs and avoid delays to clinical trials. Set up and changeover costs and times for an aerosol line are significant, so it is important to allow sufficient manufacturing time and effectively plan quantities taking future trial requirements into consideration.

    As mentioned above, commercial units may also have text embossed on their base. This can form part of the product identification and therefore should not be copied on placebo units. Placebo units will have blank bases, differentiating them from commercially-sourced actives. To eliminate this difference, it is necessary to cover the bases of both units in the same way. Various methods are available to achieve this.

    It is also necessary to de-label commercial units and change the appearance of actuators on active and placebo units so that they are different from those on the commercial product. This generally requires the removal of embossed markings. Since actuator designs are protected, it is not possible to simply copy these. The only way to obtain these for placebo units is to purchase additional commercial units, remove the active aerosol and replace it with a placebo aerosol. One way of limiting this cost is to supply patients with a single actuator and multiple aerosols for a clinical trial.

    Dry-Powder Inhalers (DPIs)
    Many recently developed inhalers do not use aerosol technology, and involve patients drawing powder into their airways themselves. This approach is believed to improve dispersal of the drug in the airways. Examples of leading DPIs include Advair/Seretide, Pulmicort, Spiriva and Foradil. Each DPI is based on a unique design, so different blinding strategies are required for each.

    Capsule-Based DPIs
    Active powders for Spiriva and Foradil are provided in hard gelatine capsules. In order to take a dose of these products, patients insert a capsule into the inhaler unit, depress a button to pierce the capsule and inhale the contents through a mouthpiece. Converting the inhaler unit itself for use in a trial is straightforward, and involves removing or obscuring commercial labels or printing on the inhaler body. The difficult part of the process is producing placebo capsules and blisters that match the active commercial product.

    Plain capsule shells that match those used in these products can be readily sourced, but lack the printing that appears on the commercial product which cannot be copied. As a result, it is necessary to remove printing from commercial capsules, obscure it or print something similar in appearance onto the placebo capsules. These capsules are typically packaged in high-barrier films, suggesting that removing product from its original packaging may affect its stability. Analytical support for the process is therefore essential.

    Capsules should be manufactured using an inert filler that has similar appearance, density and behavior to the active blend contained in commercial capsules. Particle size analysis can help in the selection of a closely matching powder. It is also necessary to choose the correct technology to fill the capsules with an appropriate weight of powder. Fill weights for these products are generally very low, and there are several options now available to manufacture large volumes of capsules with accurate fill weights using modern modular based capsule-filling equipment or smaller volumes for early phase studies on equipment such as the Xcelodose system.

    Packaging the placebo capsules in a manner that matches that of the active commercial product can be challenging, as branded blister packs cannot be copied. It is also possible that blister-packaging technology not available to most clinical supplies departments was used to produce the blisters (such as tropicalized blister packs). Again, this can make it difficult to produce matching packs. Therefore, the options are to remove or obscure branding from commercial packs, while ensuring that the approach used does not affect product integrity. Repacking the active and packing the placebo in plain packaging is also an option, however there may be stability issues with such an approach, so analytical support for repackaging is essential.  

    Reservoir-Based DPIs
    Some DPIs, such as AstraZeneca’s Turbohaler design or the Asmanex Twisthaler, contain a reservoir of powder containing the active ingredient. In principle, it should be possible to convert these units to placebo simply by disassembling them, removing the active powder and then reclosing the units. However, there are complications in this process:
    • Opening the units without causing damage requires special tooling
    • Wash methods need to be developed to remove all traces of the active ingredient from the inhaler unit; rinse methods must be developed to ensure that solvents are also removed.
    • Containment/extraction units are required to remove active dust and solvent from the atmosphere during the process.
    • Analytical tests required to prove that active ingredient has been removed.
    • Specialized equipment and tooling is required to re-assemble the units, again without damaging them.

    Typically the active powder in the reservoir is replaced with an inert placebo powder, but this approach is not always used. Powder doses delivered by this device are so low that they are believed to be undetectable to the patient. As with other inhalers, commercial labels and markings need to be removed or obscured on each unit so that clinical trial units appear different from commercial units.

    Blister-Based DPIs
    In the therapeutic area of asthma and COPD, the best known inhaler unit employing blister strips to deliver active powder for each dose is GSK’s accuhaler/diskhaler. This unit employs a 60-dose blister strip, with a specific dose of drug in each blister pocket. Each time a patient takes a dose he pulls a trigger, which advances the blister strip to the next full pocket and the dose counter to the next number. Disassembly and reassembly of this DPI is highly complex, and therefore the most difficult DPI to convert to placebo. GSK has invested millions of dollars in a robotic line for filling blister strips and assembling these units. Replicating this technology in a typical clinical supplies unit for a few hundred, or indeed thousand, placebo units for clinical trials is not feasible. While alternative approaches can be developed, these still involve significant time, cost and complexity that may exceed the resources and funds available to an in-house clinical supplies unit.

    Use of a double-blind, double-dummy design will enable companies developing new inhalation products to perform unbiased comparative trials against market-leading products. However, significant engineering and analytical work is required to convert commercial inhalers to placebos. As a result, it is essential that planning for this type of project begins well in advance of any proposed clinical trial start date. Even if time is available, the cost of automating such a process for a one-off comparative study is huge. If a trial requires only a few thousand comparator inhaler units to be converted to placebo, this can result in very high costs for each unit produced. It is worth bearing in mind that while this cost may be a barrier to an in-house clinical supplies department working on a limited number of trials, it may be less of a barrier to a contractor working with several companies with several trials each. By spreading the cost of developing and equipping this process across several clients and trials, a contractor may be more willing to invest in developing one of these conversion processes. From the industry’s perspective, outsourcing production of placebo units could bring double-blind inhaler studies within reach.

    References
    1. Inhalation & Nasal Spray Generic Drugs 2012, Drugs, 2010. http://www.espicom.com/prodcat2.nsf/Product_ID_Lookup/00001693?OpenDocument


    Martin Lamb is vice president Business Development, at Almac. He can be reached at martin.lamb@almacgroup.com.
    Related Searches
    • Outsourcing
    • Capsules
    • Clinical Materials
    • Filling
    Suggested For You
    Epizyme Earns $10M GSK Milestone Epizyme Earns $10M GSK Milestone
    GSK Invests $139M to Expand Benlysta Capacity  GSK Invests $139M to Expand Benlysta Capacity
    Quality Risk Management Quality Risk Management
    Veeva Systems Expands Leadership Team Veeva Systems Expands Leadership Team
    Mayne Pharma Acquires GSK Dermatology Assets Mayne Pharma Acquires GSK Dermatology Assets
    Almac Clinical Services Completes Successful Inspection Almac Clinical Services Completes Successful Inspection
    Continuous Pharmaceutical Processes and Their Demands Continuous Pharmaceutical Processes and Their Demands
    QuickSTAT, Almac Partner on Logistics Management Program QuickSTAT, Almac Partner on Logistics Management Program
    19  Boehringer-Ingelheim 19 Boehringer-Ingelheim
    Successful Orphan Drug Launch in Europe Successful Orphan Drug Launch in Europe
    Amgen Opens Next-Gen Bio-Mfg. Facility in Singapore Amgen Opens Next-Gen Bio-Mfg. Facility in Singapore
    Almac Adds Marketing Directors Almac Adds Marketing Directors
    Gaylord Chemical Gains CEP Certificate Gaylord Chemical Gains CEP Certificate
    New Compounding Legislation New Compounding Legislation
    Almac Names BD VP for Clinical Services Unit Almac Names BD VP for Clinical Services Unit

    Related Features

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21


    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21


    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20

    • Drug Delivery
      Wet Wipes Increased Prevalence in Drug Development

      Wet Wipes Increased Prevalence in Drug Development

      A number of factors including patient preference are driving the growth of wet wipes in pharma.
      John Waddell, Business Development Director – Pharma, PDI Contract Manufacturing 10.14.20

    • Drug Delivery
      Not Your Father’s Oral Thin Film

      Not Your Father’s Oral Thin Film

      A look at how oral film drug delivery is evolving.
      Rodolphe Obeid, Vice President of Operations, IntelGenx 06.04.20


    • Drug Delivery | Regulatory Affairs
      Regulatory Overhaul for Medical Devices

      Regulatory Overhaul for Medical Devices

      Implications for the pharmaceutical industry.
      Elizma Parry, Director, Global Clinical Practice, Maetrics 06.04.20

    • Drug Delivery
      CEO Spotlight: Will Downie

      CEO Spotlight: Will Downie

      Vectura’s chief executive talks trends in the inhaled-drug market, and the company’s transition into a CDMO
      Tim Wright, Editor, Contract Pharma 04.01.20

    • Clinical Trials
      Gene Therapy Trials

      Gene Therapy Trials

      Applications and the limitations of real-world data.
      Karen Ooms, Executive Vice President and Head of Statistics, Quanticate 09.16.19

    Trending
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement With EU
    • Obituary Notice: Russell “Russ” Haines
    • Resilience Acquires Ology Bioservices
    • Johnson & Johnson 1Q Results
    • Sartorius Expands In The UK
    Breaking News
    • Waters and Genovis Enter Biopharmaceutical Partnership
    • Frontage Acquires Ocean Ridge Biosciences
    • AGC Biologics Expands Partnership with Rocket Pharmaceuticals
    • TraceLink Introduces Opus Platform
    • Evotec to Build Second Biologics Mfg. Facility in Toulouse
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Probiotic Strain Evidenced to Reduce Iron Deficiency/Anemia Risk
    Longvida Curcumin Extract Receives ANVISA Approval in Brazil
    Curcugen Curcumin Formulation Evidenced to Attenuate Post-Exercise Inflammation
    Coatings World

    Latest Breaking News From Coatings World

    Keim-additec Hires Tyler John as Technical Sales Manager
    Nouryon Appoints Julie Aslaksen to Board of Directors
    RadTech Announces New Board Members, Secretary, Honorary Lifetime Member
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    J&J’s Veritas Vision System Receives FDA Clearance and CE Mark
    Viz.ai’s AI-Powered Platform Can Improve Outcomes for Stroke Patients
    FDA Breakthrough Device Designation Granted for pdSTIM System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Waters and Genovis Enter Biopharmaceutical Partnership
    Frontage Acquires Ocean Ridge Biosciences
    AGC Biologics Expands Partnership with Rocket Pharmaceuticals
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    How Do Americans Feel About Diversity in Beauty Advertising?
    Estée Lauder Companies Reaffirms Sustainability Goals for Earth Month
    Coty’s Lancaster Earns C2C Certified Material Health Certificate
    Happi

    Latest Breaking News From Happi

    FDA Cites Disinfection Issues at Proposed Vaccine Production Site
    It's Official! L'Oréal Gets New CEO on May 1
    New Beauty Brand sk*p Wants to Break Addiction to Plastic
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Global Graphics unveils new SmartDFE
    Channeled Resources installs new slitter in Toronto facility
    Kao Collins launches new website for printing inks and services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversation Launches Wipes Dispenser
    Because Market Debuts Premium Plus Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Spinal Elements' Lucent 3D Additive Manufactured Interbodies Earn FDA Nod
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI Appoints imec, Soitec Executives to Europe Advisory Board
    TechBlick Announces Agenda For Next Printed, Hybrid, Structural, 3D Electronics Virtual Event
    NREL Takes Novel Approach to 3D-Printed Water Power Prototypes

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login